亿帆医药(002019.SZ)：盐酸沙丙蝶呤散剂收到药品注册受理通知书

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) has received a production registration acceptance notice from the National Medical Products Administration for its hydrochloride sapropterin dihydrochloride granules, indicating progress in its product development pipeline [1] Group 1: Company Developments - Yifan Pharmaceutical's wholly-owned subsidiary, Sichuan Defeng Pharmaceutical Co., Ltd., has recently received the acceptance notice for the production registration of sapropterin hydrochloride granules [1] - The product is intended for patients with hyperphenylalaninemia (HPA) caused by tetrahydrobiopterin (BH4) responsive phenylketonuria (PKU), applicable for adults and children over one month old [1]